Drugs more commonly prescribed for renal patients that cause QT interval prolongation, and their interaction in the onset of malignant arrhythmia
| Drug | Action | Comment |
| Macrolides | Antimicrobial | Bioavailability of digoxin is also increased by erythromycin by a change in gut flora and this must be monitored closely. See also comment on interaction with calcineurin inhibitors (CNI) below. |
| Quinolones | Antimicrobial | |
| Co-trimoxazole | Post-transplant prophylaxis | |
| Triazole antifungals | Post-transplant prophylaxis | Usually given until 6 months post-transplant |
| Tacrolimus | Transplant immunosuppression | These CNI agents are substrates of the cytochrome p450 (CYP) 3A4 enzyme. Many commonly prescribed drugs, most notably verapamil and macrolide antibiotics, are strong inhibitors of this enzyme. The consequent increase in serum CNI concentration can result in significant hyperkalaemia and nephrotoxicity. Tacrolimus has also been associated with supraventricular and ventricular tachyarrhythmias, including torsades de pointes. Thus, drugs which act on the CYP enzymes, should be used with caution in transplant recipients, and CNI drug concentrations must be closely monitored. |
| Ciclosporin | Transplant immunosuppression | |
| Quinine | Dialysis induced cramps | |
| Benzodiazepines | Dialysis induced cramps | |
| Domperidone | Dialysis induced nausea and postural drop | |
| Midodrine | Refractory hypotension | |
| Selective serotonin reuptake inhibitors (SSRIs) | High prevalence of depression | |
| Antihistamines | Uraemic itch |